Journal of Shandong University (Health Sciences) ›› 2026, Vol. 64 ›› Issue (9): 1-7.doi: 10.6040/j.issn.1671-7554.0.2026.0971

• Expert Consensus •    

Shandong Provincial expert consensus on perioperative quality control for VATS/RATS in non-small cell lung cancer(2026 Edition)

Thoracic Surgery Branch, Shandong Medical Association   

  1. 〓
  • Published:2026-09-09

PDF (PC)

29

Abstract: Lung cancer ranks first in both incidence and mortality among all malignancies worldwide and in China. Surgical resection remains the most effective treatment for early-stage non-small cell lung cancer(NSCLC). In alignment with the "Healthy China 2030" initiative, a series of policies and guidelines have been introduced to enhance quality control in cancer diagnosis and treatment, with lung cancer identified as one of the priority cancer types for such oversight. In response, the Thoracoscopy Committee of the Shandong Provincial Endoscopic Surgery Quality Control Center developed the Shandong Provincial Expert Consensus on Perioperative Quality Control for Video-Assisted Thoracoscopic Surgery(VATS)/Robot-Assisted Thoracoscopic Surgery(RATS)in Non-Small Cell Lung Cancer(2025 Edition). During its implementation, medical institutions across Shandong Province accumulated substantial clinical experience and provided constructive feedback regarding several quality control aspects that could be further optimized. Based on this feedback and a comprehensive review of the 2025 experience, the Thoracic Surgery Branch of the Shandong Medical Association has updated and refined the consensus, resulting in the present 2026 Edition. This updated version is intended to promote continuous improvement and guide perioperative management of NSCLC toward greater precision and efficiency across thoracic surgery practice in Shandong Province.

Key words: Non-small cell lung cancer, Thoracoscopic surgery, Perioperative period, Quality control, Expert consensus

CLC Number: 

  • R734.2
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
[2] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[3] Lin Z, Cheng X. The future and challenges of robotics in lung cancer surgery[J]. Tumor, 2024, 44(6): 631-641.
[4] Casiraghi M, Cara A, Mazzella A et al. 1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience[J]. Lung Cancer,2024, 195:107903. DOI: 10.1016/j.lungcan.2024.107903
[5] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报(医学版), 2025, 63(12): 1-5.
[6] Forde P M, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985.
[7] Cascone T, Awad M M, Spicer J D, et al. Perioperative Nivolumab in resectable lung cancer[J]. N Engl J Med, 2024, 390(19): 1756-1769.
[8] Heymach J V, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for resectable non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(18): 1672-1684.
[9] Spicer J D, Garassino M C, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer(KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2024, 404(10459): 1240-1252.
[10] Feldman H, Sepesi B, Leung C H, et al. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer [J]. J Thorac Cardiovasc Surg, 2024, 167(4): 1444-1453.
[11] NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version5.2026 [EB/OL]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450.
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南 2026[M]. 北京: 人民卫生出版社, 2026: 4.
[13] 中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版)[J]. 中华医学杂志, 2024, 104(34): 3175-3213.
[14] Wakelee H A, Altorki N K, Zhou C, et al. IMpower010: Final disease-free survival(DFS)and second overall survival(OS)interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer(NSCLC)[C]. ASCO Annual Meeting, 2024.
[15] Wu Y L, Dziadziuszko R, Ahn J S, et al. Alectinib in resected ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(14): 1265-1276.
[16] Wu Y L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
[17] Herbst R S, Wu Y L, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840.
[18] Hung H Y, Tseng Y H, Chao H S, et al. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer[J]. PLoS One, 2020, 15(10): e0236503. DOI:10.1371/journal.pone.0236503
[19] Yamamichi T, Ichinose J, Omura K et al. Impact of postoperative complications on the long-term outcome in lung cancer surgery[J]. Surg Today, 2022, 52(9): 1254-1261.
[1] LYU Jinfeng, ZHAO Hui, QIN Xiangrong, GONG Yanwen, MAO Haiting, MENG Jing. Validation and application of autoverification rules for blood analysis [J]. Journal of Shandong University (Health Sciences), 2026, 64(8): 107-113.
[2] LIANG Chen, YAO Lijuan, LYU Longfei, TANG Ze, QIN Da, CUI Youbin,YU Xiaoqi. Application of 3D reconstruction combined with CT-guided puncture localization in minimally invasive treatment of pulmonary ground-glass nodules [J]. Journal of Shandong University (Health Sciences), 2026, 64(5): 74-82.
[3] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[4] Intelligent Orthopedics Subgroup of Chinese Association of Orthopedic, Subgroup for Prevention and Control of Spinal and Spinal Cord Injury Diseases of Professional Committee for Prevention and Control of Spinal Diseases of Chinese Preventive Medicine Association. Expert consensus on measurement sites and annotation of artificial intelligence-based spinal degenerative imaging(2025) [J]. Journal of Shandong University (Health Sciences), 2026, 64(2): 1-10.
[5] Intelligent Orthopedics Subgroup of Chinese Association of Orthopedic, Subgroup for Prevention and Control of Spinal and Spinal Cord Injury Diseases of Professional Committee for Prevention and Control of Spinal Diseases of Chinese Preventive Medicine Association. Expert consensus on robot-assisted transforaminal lumbar interbody fusion surgical techniques [J]. Journal of Shandong University (Health Sciences), 2026, 64(2): 11-21.
[6] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[7] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[8] Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5.
[9] LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45.
[10] . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16.
[11] SI Haipeng, WANG Chongyi, GONG Guiqing, ZHANG Wencan, GUO Yingjun, WANG Kaibin,FENG Yunze, XU Wanlong, LI Le. Application progress of enhanced recovery after surgery in spine surgery [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 8-17.
[12] ZHANG Yang, LI Xiaoxu. Research progress of enhanced recovery after surgery for fracture treatment [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 18-25.
[13] TANG Ning, HUANG Xiaoli, SONG Guihua. Research progress of nutrition management in elderly patients with hip fracture surgery [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 42-47.
[14] Orthopaedic Rehabilitation Special Committee of Chinese Speaking Orthopaedic Society. Expert consensus on accelerated recovery of knee function after total knee arthroplasty [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 48-61.
[15] Writing experts: BAN Yanli, ZHAO Ying, LI Hua, LIU Wei, RONG Fengnian, ZHAO Shuping, CUI Baoxia. Expert consensus of practical clinical classification system with optimal surgical strategy for cesarean scar pregnancy [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 1-10.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd